As a member of the HER family, EGFR is associated with unfavorable tumor prognosis; its expression is detected in approximately 40% of breast cancers and overexpression can predict a poor response to endocrine therapy among breast cancer patients [21,22]. Here, EGFR is linked to breast carcinoma.